Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
Michele CeaAntonia CagnettaSophia AdamiaChirag AcharyaYu-Tzu TaiMariateresa FulcinitiHiroto OhguchiAditya MunshiPrakrati AcharyaManoj K BhasinLei ZhongRuben CarrascoFiammetta MonacelliAlberto BallestreroPaul RichardsonMarco GobbiRoberto M LemoliNikhil MunshiTeru HideshimaAlessio NencioniDharminder ChauhanKenneth C AndersonPublished in: Blood (2015)
Multiple myeloma (MM) is characterized by a highly unstable genome, with aneuploidy observed in nearly all patients. The mechanism causing this karyotypic instability is largely unknown, but recent observations have correlated these abnormalities with dysfunctional DNA damage response. Here, we show that the NAD(+)-dependent deacetylase SIRT6 is highly expressed in MM cells, as an adaptive response to genomic stability, and that high SIRT6 levels are associated with adverse prognosis. Mechanistically, SIRT6 interacts with the transcription factor ELK1 and with the ERK signaling-related gene. By binding to their promoters and deacetylating H3K9 at these sites, SIRT6 downregulates the expression of mitogen-activated protein kinase (MAPK) pathway genes, MAPK signaling, and proliferation. In addition, inactivation of ERK2/p90RSK signaling triggered by high SIRT6 levels increases DNA repair via Chk1 and confers resistance to DNA damage. Using genetic and biochemical studies in vitro and in human MM xenograft models, we show that SIRT6 depletion both enhances proliferation and confers sensitization to DNA-damaging agents. Our findings therefore provide insights into the functional interplay between SIRT6 and DNA repair mechanisms, with implications for both tumorigenesis and the treatment of MM.
Keyphrases
- dna repair
- dna damage response
- dna damage
- oxidative stress
- signaling pathway
- induced apoptosis
- ischemia reperfusion injury
- multiple myeloma
- transcription factor
- genome wide
- pi k akt
- emergency department
- copy number
- histone deacetylase
- endothelial cells
- gene expression
- cell proliferation
- newly diagnosed
- end stage renal disease
- ejection fraction
- cell death
- combination therapy
- genome wide identification
- patient reported outcomes
- drug induced
- protein kinase
- dna binding